Cognizant signs deal with AstraZeneca

To provide biostatistics and medical reporting services

IT firm Cognizant has agreed a multi-year deal with AstraZeneca to deliver comprehensive biostatistics and medical reporting services.

Under the agreement, Cognizant will provide centralised statistical programming, statistical analysis, medical writing, and document publishing services, spanning the entire chain of clinical data reporting.

This will enable AstraZeneca to increase operational efficiency, reduce cycle times, and optimise costs, Cognizant said.

AstraZeneca will continue to own and manage key scientific and medical activities associated with the design of clinical trial programmes, and the interpretation of data from them.

‘Cognizant will help us streamline our clinical development operations. This is key to our business transformation aimed at achieving greater efficiency, agility, flexibility, and global competitiveness – all of which are crucial to clinical trials and development of new drugs,’ said Karin Wingstrand, vice president and head of clinical development at AstraZeneca.

AstraZeneca first engaged Cognizant in 2004 to provide business process and technology solutions spanning discovery, clinical, manufacturing, and commercial operations.

Since 2008, Cognizant has also been providing centralised data management services for AstraZeneca’s global clinical development programmes, and application maintenance services to AstraZeneca’s global enterprise in the business-critical areas of research, clinical development, and sales and marketing.

Companies